Cibc World Markets Corp Acquires Shares of 21,076 ADMA Biologics, Inc. (NASDAQ:ADMA)

Cibc World Markets Corp purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 21,076 shares of the biotechnology company's stock, valued at approximately $361,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Natixis Advisors LLC acquired a new position in ADMA Biologics during the third quarter worth $345,000. Mutual of America Capital Management LLC bought a new stake in shares of ADMA Biologics during the 3rd quarter worth about $701,000. Thrivent Financial for Lutherans acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at about $3,802,000. Intech Investment Management LLC bought a new stake in ADMA Biologics during the third quarter worth approximately $1,242,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in ADMA Biologics by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,401,533 shares of the biotechnology company's stock valued at $48,007,000 after purchasing an additional 249,412 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Trading Down 0.5 %

Shares of ADMA traded down $0.10 during trading hours on Tuesday, reaching $20.22. The stock had a trading volume of 2,401,540 shares, compared to its average volume of 3,363,541. The company has a market cap of $4.78 billion, a P/E ratio of 72.21 and a beta of 0.60. ADMA Biologics, Inc. has a 52 week low of $5.90 and a 52 week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a 50-day moving average of $16.84 and a 200 day moving average of $18.07.

Remove Ads

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.